In accordance with these published results, combined analysis of expression profiling data from normal hematopoietic cells and AML patient samples demonstrated physiological NKX2-3 activity in stem cells and aberrant expression in patients with KMT2A rearrangements and complex karyotypes (Figure S4). This evidence concerns the gene KMT2A and acute myeloid leukemia.